高级检索
    程颖, 张良. 帕博利珠单抗联合化疗对亚洲PD-L1阴性的晚期非小细胞肺癌患者的疗效与安全性[J]. 循证医学, 2023, 23(4): 213-224. DOI: 10.12019/j.issn.1671-5144.2023.04.005
    引用本文: 程颖, 张良. 帕博利珠单抗联合化疗对亚洲PD-L1阴性的晚期非小细胞肺癌患者的疗效与安全性[J]. 循证医学, 2023, 23(4): 213-224. DOI: 10.12019/j.issn.1671-5144.2023.04.005
    shu
    CHENG Ying, ZHANG Liang. Efficacy and Safety of Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer Without Tumor PD-L1 Expression in Asian Patients[J]. Journal of Evidence-Based Medicine, 2023, 23(4): 213-224. DOI: 10.12019/j.issn.1671-5144.2023.04.005
    Citation: CHENG Ying, ZHANG Liang. Efficacy and Safety of Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer Without Tumor PD-L1 Expression in Asian Patients[J]. Journal of Evidence-Based Medicine, 2023, 23(4): 213-224. DOI: 10.12019/j.issn.1671-5144.2023.04.005
    shu

    帕博利珠单抗联合化疗对亚洲PD-L1阴性的晚期非小细胞肺癌患者的疗效与安全性

    Efficacy and Safety of Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer Without Tumor PD-L1 Expression in Asian Patients

      摘要
      • HTML全文
      • 参考文献(14)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回